Detalhe da pesquisa
1.
Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial.
Lancet Oncol
; 25(3): 317-325, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38342115
2.
Impact of the Breast Cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study.
J Natl Compr Canc Netw
; 22(2): 99-107, 2024 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38437792
3.
Neratinib: an option for HER2-positive metastatic breast cancer.
Clin Adv Hematol Oncol
; 18 Suppl 15(9): 1-20, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-33843838
4.
Neratinib in the early-stage/extended adjuvant breast cancer patient.
Clin Adv Hematol Oncol
; 18 Suppl 12(8): 1-20, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33843843
5.
Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study.
Oncologist
; 24(9): 1153-1158, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30833486
6.
Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancer.
Breast J
; 25(5): 880-888, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31290203
7.
Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.
Mol Cell Proteomics
; 14(7): 1959-76, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25953087
8.
Highlights in metastatic breast cancer from the 2021 San Antonio Breast Cancer Symposium: commentary.
Clin Adv Hematol Oncol
; 20 Suppl 4(1): 15-18, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35343938
9.
Highlights in early and metastatic breast cancer from the 2020 San Antonio Breast Cancer Symposium: commentary.
Clin Adv Hematol Oncol
; 19 Suppl 9(2): 18-23, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33843924
10.
"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy.
Breast Cancer Res
; 17(1): 150, 2015 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27391598
11.
Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute.
Breast Cancer Res Treat
; 154(1): 89-97, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26456573
12.
Best use of neratinib in patients with early-stage breast cancer.
Clin Adv Hematol Oncol
; 18 Suppl 12(8): 11-16, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33843846
13.
Highlights in metastatic breast cancer from the 2019 San Antonio Breast Cancer Symposium: commentary.
Clin Adv Hematol Oncol
; 18 Suppl 4(1): 17-19, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33843864
14.
Neratinib: clinical trial data in HER2-positive metastatic breast cancer.
Clin Adv Hematol Oncol
; 18 Suppl 15(9): 7-11, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-33843840
15.
Neratinib in the early-stage/extended adjuvant breast cancer patient: Q&A.
Clin Adv Hematol Oncol
; 18 Suppl 12(8): 16-17, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33843847
16.
Neratinib: an option for HER2-positive metastatic breast cancer--Q&A.
Clin Adv Hematol Oncol
; 18 Suppl 15(9): 15-17, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-33843842
17.
Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples.
Breast Cancer Res Treat
; 148(2): 315-25, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25338319
18.
Clinical roundtable monograph: effective management of quality of life in metastatic breast cancer.
Clin Adv Hematol Oncol
; 12(2 Suppl 4): 1-14; quiz 15, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24870601
19.
Targeting HER2/HER3 co-mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy.
Cancer Rep (Hoboken)
; 7(3): e1954, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38441358
20.
Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]).
J Clin Oncol
; 42(12): 1344-1349, 2024 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38335467